ST-Elevation Myocardial Infarction: Preventive Percutaneous Coronary Intervention in the Non-Culprit Vessel
Konstantinos Triantafyllou
Abstract
Konstantinos Triantafyllou
Abstract
Patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD) have poorer outcomes after primary percutaneous coronary intervention (PCI) compared to those with one-vessel coronary artery disease. Current STEMI guidelines recommend revascularization of the infarct related artery (IRA) only during primary PCI, while PCI for non-IRA lesions should be performed after objective evidence of residual ischemia. Evidence regarding the optimal management strategy for non-IRA lesions in STEMI patients with MVD has been limited and mainly based on retrospective, contradictory and probably biased data. A recently published randomized study, PRAMI, challenges the guidelines since preventive acute multi-vessel PCI for significant stenoses in non-IRAs has been associated with a reduction of major adverse cardiovascular events (MACE) compared to PCI limited to the IRA. A review of the literature and a discussion about the implications of the PRAMI study regarding the optimal revascularization strategy for STEMI with MVD are presented herein.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD) have poorer outcomes after primary percutaneous coronary intervention (PCI) compared to those with one-vessel coronary artery disease. Current STEMI guidelines recommend revascularization of the infarct related artery (IRA) only during primary PCI, while PCI for non-IRA lesions should be performed after objective evidence of residual ischemia. Evidence regarding the optimal management strategy for non-IRA lesions in STEMI patients with MVD has been limited and mainly based on retrospective, contradictory and probably biased data. A recently published randomized study, PRAMI, challenges the guidelines since preventive acute multi-vessel PCI for significant stenoses in non-IRAs has been associated with a reduction of major adverse cardiovascular events (MACE) compared to PCI limited to the IRA. A review of the literature and a discussion about the implications of the PRAMI study regarding the optimal revascularization strategy for STEMI with MVD are presented herein.
Key concepts: Medicine, Conventional PCI, Mace, Percutaneous coronary intervention, Cardiology, Myocardial infarction, Internal medicine, Culprit